Log in

Relevant bibliographies by topics / [18F]flutemetamol / Journal articles

To see the other types of publications on this topic, follow the link: [18F]flutemetamol.

Journal articles on the topic '[18F]flutemetamol'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '[18F]flutemetamol.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kang, ShinWoo, Jinho Kim, Sang-Yoon Lee, Nobuyuki Okamura, and Keun-A. Chang. "MicroPET Imaging Assessment of Brain Tau and Amyloid Deposition in 6 × Tg Alzheimer’s Disease Model Mice." International Journal of Molecular Sciences 23, no. 10 (2022): 5485. http://dx.doi.org/10.3390/ijms23105485.

Full text

Abstract:

Alzheimer’s disease (AD) is characterized by the deposition of extracellular amyloid plaques and intracellular accumulation of neurofibrillary tangles (NFT). Amyloid beta (Aβ) and tau imaging are widely used for diagnosing and monitoring AD in clinical settings. We evaluated the pathology of a recently developed 6 × Tg − AD (6 × Tg) mouse model by crossbreeding 5 × FAD mice with mice expressing mutant (P301L) tau protein using micro-positron emission tomography (PET) image analysis. PET studies were performed in these 6 × Tg mice using [18F]Flutemetamol, which is an amyloid PET radiotracer; [1

APA, Harvard, Vancouver, ISO, and other styles

2

Ossenkoppele, Rik, Ruben Smith, Tomas Ohlsson та ін. "Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease". Neurology 92, № 6 (2019): e601-e612. http://dx.doi.org/10.1212/wnl.0000000000006875.

Full text

Abstract:

ObjectiveTo examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cortical thickness and neuropsychological function across the preclinical and clinical spectrum of Alzheimer disease (AD).MethodsWe included 106 participants from the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) study, of whom 33 had preclinical AD (Aβ-positive cognitively normal individuals), 25 had prodromal AD (Aβ-positive mild cognitive impairment), and 48 had probable AD dementia. All underwent [18F]flortaucipir (tau) and structural MRI (cortical

APA, Harvard, Vancouver, ISO, and other styles

3

Hellberg, Sanna, Johanna Silvola, Heidi Liljenbäck, et al. "Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques." Molecules 24, no. 6 (2019): 1072. http://dx.doi.org/10.3390/molecules24061072.

Full text

Abstract:

Atherosclerosis is characterized by the accumulation of oxidized lipids in the artery wall, which triggers an inflammatory response. Oxidized low-density lipoprotein (ox-LDL) presents amyloid-like structural properties, and different amyloid species have recently been recognized in atherosclerotic plaques. Therefore, we studied the uptake of the amyloid imaging agent [18F]Flutemetamol in atherosclerotic plaques. The binding of [18F]Flutemetamol to human carotid artery plaque was studied in vitro. In vivo uptake of the tracer was studied in hypercholesterolemic IGF-II/LDLR−/−ApoB100/100 mice an

APA, Harvard, Vancouver, ISO, and other styles

4

Müller, Ebba Gløersen, Trine Holt Edwin, Bjørn Heine Strand, Caroline Stokke, Mona Elisabeth Revheim, and Anne-Brita Knapskog. "Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?" Journal of Alzheimer's Disease 85, no. 1 (2022): 197–205. http://dx.doi.org/10.3233/jad-215046.

Full text

Abstract:

Background: Patients with Alzheimer’s disease (AD) show heterogeneity in clinical progression rate, and we have limited tools to predict prognosis. Amyloid burden from 18F-Flutemetamol positron emission tomography (PET), as measured by standardized uptake value ratios (SUVR), might provide prognostic information. Objective: We investigate whether 18F-Flutemetamol PET composite or regional SUVRs are associated with trajectories of clinical progression. Methods: This observational longitudinal study included 94 patients with clinical AD. PET images were semi-quantified with normalization to pons

APA, Harvard, Vancouver, ISO, and other styles

5

Hammers, Dustin B., Taylor J. Atkinson, Bonnie C. A. Dalley, et al. "Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults." American Journal of Alzheimer's Disease & Other Dementiasr 32, no. 6 (2017): 320–28. http://dx.doi.org/10.1177/1533317517698795.

Full text

Abstract:

Little research exists examining the relationship between beta-amyloid neuritic plaque density via [18F]flutemetamol binding and cognition; consequently, the purpose of the current study was to compare cognitive performances among individuals having either increased amyloid deposition (Flute+) or minimal amyloid deposition (Flute−). Twenty-seven nondemented community-dwelling adults over the age of 65 underwent [18F]flutemetamol amyloid-positron emission tomography imaging, along with cognitive testing using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and sel

APA, Harvard, Vancouver, ISO, and other styles

6

Walker, Z., F. Inglis, C. Sadowsky, et al. "Reproducibility of [18f]flutemetamol pet amyloid image interpretation." Journal of the Neurological Sciences 333 (October 2013): e352. http://dx.doi.org/10.1016/j.jns.2013.07.1294.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Heeman, Fiona, Maqsood Yaqub, Janine Hendriks, et al. "Parametric imaging of dual-time window [18F]flutemetamol and [18F]florbetaben studies." NeuroImage 234 (July 2021): 117953. http://dx.doi.org/10.1016/j.neuroimage.2021.117953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ikonomovic, Milos D., Christopher J. Buckley, Eric E. Abrahamson та ін. "Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease". Acta Neuropathologica 140, № 4 (2020): 463–76. http://dx.doi.org/10.1007/s00401-020-02175-1.

Full text

Abstract:

Abstract Specificity and sensitivity of positron emission tomography (PET) radiopharmaceuticals targeting fibrillar amyloid-β (Aβ) deposits is high for detection of neuritic Aβ plaques, a mature form of Aβ deposits which often have dense Aβ core (i.e., cored plaques). However, imaging-to-autopsy validation studies of amyloid PET radioligands have identified several false positive cases all of which had mainly diffuse Aβ plaques (i.e., plaques without neuritic pathology or dense amyloid core), and high amyloid PET signal was reported in the striatum where diffuse plaques predominate in Alzheime

APA, Harvard, Vancouver, ISO, and other styles

9

Yeo, Jing Ming, Briony Waddell, Zubair Khan, and Suvankar Pal. "A SYSTEMATIC REVIEW & META-ANALYSIS OF F-18-LABELLED AMYLOID IMAGING IN ALZHEIMER'S DISEASE." Journal of Neurology, Neurosurgery & Psychiatry 86, no. 11 (2015): e4.142-e4. http://dx.doi.org/10.1136/jnnp-2015-312379.51.

Full text

Abstract:

IntroductionThere has been recent interest in the use of fluorine-18-labelled (18F) tracers in amyloid imaging as they have longer half-lives compared to 11C-labelled Pittsburgh compound-B (11C-PIB). This systematic review and meta-analysis aims to assess the sensitivity and specificity of 18F tracers florbetapir, florbetaben and flutemetamol in diagnosing Alzheimer's disease (AD).MethodsWe systematically searched MEDLINE and EMBASE for relevant studies published from January 1980 to March 2014. We pooled the studies comparing imaging findings in AD and normal controls (NC) in a meta-analysis,

APA, Harvard, Vancouver, ISO, and other styles

10

Fiona, Heeman, Yaqub Maqsood, Lopes Alves Isadora, et al. "Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies." Journal of Cerebral Blood Flow & Metabolism 41, no. 3 (2020): 579–89. https://doi.org/10.1177/0271678X20918029.

Full text

Abstract:

<strong>Abstract</strong> Global and regional changes in cerebral blood flow (CBF) can result in biased quantitative estimates of amyloid load by PET imaging. Therefore, the current simulation study assessed effects of these changes on amyloid quantification using a reference tissue approach for [<sup>18</sup>F]flutemetamol and [<sup>18</sup>F]florbetaben. Previously validated pharmacokinetic rate constants were used to simulate time-activity curves (TACs) corresponding to full dynamic and dual-time-window acquisition protocols. CBF changes were simulated by varying the tracer delivery (<em>K<

APA, Harvard, Vancouver, ISO, and other styles

11

Aksnes, Mari, Ebba Glersen Müller, Ann Tiiman, et al. "Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer’s Disease in a Memory Clinic Cohort." Journal of Alzheimer's Disease 77, no. 2 (2020): 831–42. http://dx.doi.org/10.3233/jad-200237.

Full text

Abstract:

Background: Aggregation of amyloid-β (Aβ) is an early pathological event in Alzheimer’s disease (AD). Consequently, measures of pathogenic aggregated Aβ are attractive biomarkers for AD. Here, we use a recently developed Thioflavin-T-Fluorescence Correlation Spectroscopy (ThT-FCS) assay to quantify structured ThT-responsive protein aggregates, so-called nanoplaques, in the cerebrospinal fluid (CSF). Objective: The overall aim of this work was to assess whether ThT-FCS determined CSF nanoplaque levels could predict amyloid brain uptake as determined by 18F-Flutemetamol PET analysis. Further, we

APA, Harvard, Vancouver, ISO, and other styles

12

Lhommel, Renaud, Christine Sempoux, Adrian Ivanoiu, Lucienne Michaux, and Bernhard Gerber. "Is 18F-Flutemetamol PET/CT Able to Reveal Cardiac Amyloidosis?" Clinical Nuclear Medicine 39, no. 8 (2014): 747–49. http://dx.doi.org/10.1097/rlu.0000000000000492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Thurfjell, Lennart, Roger Lundqvist, Johan Lilja, et al. "P4-074: Automated quantification of [18F]flutemetamol amyloid imaging data." Alzheimer's & Dementia 7 (July 2011): S726. http://dx.doi.org/10.1016/j.jalz.2011.05.2095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Cho, Soo Hyun, Yeong Sim Choe, Hee Jin Kim, et al. "A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB." European Journal of Nuclear Medicine and Molecular Imaging 47, no. 8 (2019): 1938–48. http://dx.doi.org/10.1007/s00259-019-04596-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Seiffert, Alexander P., Adolfo Gómez-Grande, Alberto Villarejo-Galende, et al. "High Correlation of Static First-Minute-Frame (FMF) PET Imaging after 18F-Labeled Amyloid Tracer Injection with [18F]FDG PET Imaging." Sensors 21, no. 15 (2021): 5182. http://dx.doi.org/10.3390/s21155182.

Full text

Abstract:

Dynamic early-phase PET images acquired with radiotracers binding to fibrillar amyloid-beta (Aβ) have shown to correlate with [18F]fluorodeoxyglucose (FDG) PET images and provide perfusion-like information. Perfusion information of static PET scans acquired during the first minute after radiotracer injection (FMF, first-minute-frame) is compared to [18F]FDG PET images. FMFs of 60 patients acquired with [18F]florbetapir (FBP), [18F]flutemetamol (FMM), and [18F]florbetaben (FBB) are compared to [18F]FDG PET images. Regional standardized uptake value ratios (SUVR) are directly compared and intrap

APA, Harvard, Vancouver, ISO, and other styles

16

Auvity, Sylvain, Matteo Tonietto, Fabien Caillé, et al. "Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB." European Journal of Nuclear Medicine and Molecular Imaging 47, no. 2 (2019): 490–501. http://dx.doi.org/10.1007/s00259-019-04516-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Duff, Kevin, Kevin P. Horn, and John M. Hoffman. "Long-term Changes in 18F-Flutemetamol Uptake in Nondemented Older Adults." Alzheimer Disease & Associated Disorders 33, no. 2 (2019): 113–17. http://dx.doi.org/10.1097/wad.0000000000000293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kalheim, Lisa Flem, Tormod Fladby, Christopher Coello, Atle Bjørnerud, and Per Selnes. "[18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose." Journal of Alzheimer's Disease 62, no. 4 (2018): 1595–607. http://dx.doi.org/10.3233/jad-170582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Cho, Soo Hyun, Yeong Sim Choe, Young Ju Kim, et al. "Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions." Journal of Alzheimer's Disease 76, no. 1 (2020): 281–90. http://dx.doi.org/10.3233/jad-200079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lee, Joonho, Hong Nam Kim, Min Hye Kim та ін. "Asymmetric Amyloid-β Burden and Neurodegeneration in Late-Onset Alzheimer’s Disease Dementia". Journal of the Korean Neurological Association 39, № 3 (2021): 197–201. http://dx.doi.org/10.17340/jkna.2021.3.15.

Full text

Abstract:

We report herein a 78-year-old woman with insidiously progressive cognitive impairment and asymmetric amyloid deposition and neurodegeneration. Brain magnetic resonance imaging revealed remarkable atrophy in the right-sided temporal lobe and hippocampus. Early dynamic 18F-flutemetamol brain amyloid positron-emission tomography images showed decreased uptake in the right temporoparietal regions. Delayed images revealed amyloid deposition which was most remarkable in the right frontotemporoparietal regions. Asymmetries of amyloid burden and neuronal dysfunction are positively correlated in Alzhe

APA, Harvard, Vancouver, ISO, and other styles

21

Cho, Soo Hyun, Yeong Sim Choe, Hee Jin Kim, et al. "Correction to: A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB." European Journal of Nuclear Medicine and Molecular Imaging 47, no. 6 (2020): 1610. http://dx.doi.org/10.1007/s00259-020-04692-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Beach, Thomas G., Dietmar Rudolf Thal, Michelle Zanette, Adrian Smith, and Christopher Buckley. "Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology." Journal of Alzheimer's Disease 52, no. 3 (2016): 863–73. http://dx.doi.org/10.3233/jad-150732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Thal, Dietmar R., T. G. Beach, M. Zanetti, K. Heurling, C. Buckley, and A. Smith. "Diagnostic value of [18F]flutemetamol amyloid PET: comparison between imaging and neuropathology." Neurobiology of Aging 35 (March 2014): S22. http://dx.doi.org/10.1016/j.neurobiolaging.2014.01.115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Heurling, Kerstin, Rik Vandenberghe, Rikard Owenius, Lennart Thurfjell, Chris J. Buckley, and David J. Brooks. "Pons as an alternative reference region in [18F]flutemetamol quantification of amyloidosis." NeuroImage 52 (August 2010): S137. http://dx.doi.org/10.1016/j.neuroimage.2010.04.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ataka, Suzuka, Akitoshi Takeda, Toshikazu Mino, et al. "IC-P-034: COMPARISON OF [18F] FLUTEMETAMOL AND [11C] PIB PET IMAGES." Alzheimer's & Dementia 10 (July 2014): P21. http://dx.doi.org/10.1016/j.jalz.2014.05.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kim, Min Hye, Joonho Lee, Hong Nam Kim та ін. "Longitudinal Observation of Early-Onset Alzheimer’s Disease Dementia with Positive CSF Biomarkers/Negative Amyloid-β Positron-Emission Tomography". Journal of the Korean Neurological Association 39, № 3 (2021): 214–18. http://dx.doi.org/10.17340/jkna.2021.3.19.

Full text

Abstract:

We report a 61-year-old woman with clinical course for Alzheimer’s disease (AD) dementia and discordant amyloid-β positron-emission tomography (PET) and cerebrospinal fluid biomarkers. Brain magnetic resonance imaging revealed remarkable atrophy in the hippocampus. However, repeated delayed 18F-flutemetamol brain amyloid PET images with 1 year-interval revealed no amyloid deposition, whereas her CSF revealed low Aβ42, high total tau and p-tau181. This discordant amyloid-β PET and CSF biomarkers in this early-onset AD dementia might be associated with her low resilience or mixed pathology.

APA, Harvard, Vancouver, ISO, and other styles

27

Yamao, Tensho, Kenta Miwa, Yuta Kaneko, et al. "Deep Learning-Driven Estimation of Centiloid Scales from Amyloid PET Images with 11C-PiB and 18F-Labeled Tracers in Alzheimer’s Disease." Brain Sciences 14, no. 4 (2024): 406. http://dx.doi.org/10.3390/brainsci14040406.

Full text

Abstract:

Background: Standard methods for deriving Centiloid scales from amyloid PET images are time-consuming and require considerable expert knowledge. We aimed to develop a deep learning method of automating Centiloid scale calculations from amyloid PET images with 11C-Pittsburgh Compound-B (PiB) tracer and assess its applicability to 18F-labeled tracers without retraining. Methods: We trained models on 231 11C-PiB amyloid PET images using a 50-layer 3D ResNet architecture. The models predicted the Centiloid scale, and accuracy was assessed using mean absolute error (MAE), linear regression analysis

APA, Harvard, Vancouver, ISO, and other styles

28

Suzuki, Yuji, Yukimi Nakamura та Hironaka Igarashi. "Blood Cerebrospinal Fluid Barrier Function Disturbance Can Be Followed by Amyloid-β Accumulation". Journal of Clinical Medicine 11, № 20 (2022): 6118. http://dx.doi.org/10.3390/jcm11206118.

Full text

Abstract:

Background: Elucidation of the mechanism of amyloid-β accumulation plays an important role in therapeutic strategies for Alzheimer’s disease (AD). The aim of this study is to elucidate the relationship between the function of the blood–cerebrospinal fluid barrier (BCSFB) and the clearance of amyloid-β (Aβ). Methods: Twenty-five normal older adult volunteers (60–81 years old) participated in this PET study for clarifying the relationship between interstitial water flow and Aβ accumulation. Water dynamics were analyzed using two indices in [15O]H2O PET, the influx ratio (IR) and drain rate (DR),

APA, Harvard, Vancouver, ISO, and other styles

29

Leuzy, Antoine, Johan Lilja, Christopher J. Buckley та ін. "Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load". Neurology 95, № 21 (2020): e2834-e2844. http://dx.doi.org/10.1212/wnl.0000000000011031.

Full text

Abstract:

ObjectiveTo evaluate a novel β-amyloid (Aβ)-PET–based quantitative measure (Aβ accumulation index [Aβ index]), including the assessment of its ability to discriminate between participants based on Aβ status using visual read, CSF Aβ42/Aβ40, and post-mortem neuritic plaque burden as standards of truth.MethodsOne thousand one hundred twenty-one participants (with and without cognitive impairment) were scanned with Aβ-PET: Swedish BioFINDER, n = 392, [18F]flutemetamol; Alzheimer’s Disease Neuroimaging Initiative (ADNI), n = 692, [18F]florbetapir; and a phase 3 end-of-life study, n = 100, [18F]flu

APA, Harvard, Vancouver, ISO, and other styles

30

Seiffert, Alexander P., Adolfo Gómez-Grande, Eva Milara, et al. "Texture-Based Analysis of 18F-Labeled Amyloid PET Brain Images." Applied Sciences 11, no. 5 (2021): 1991. http://dx.doi.org/10.3390/app11051991.

Full text

Abstract:

Amyloid positron emission tomography (PET) brain imaging with radiotracers like [18F]florbetapir (FBP) or [18F]flutemetamol (FMM) is frequently used for the diagnosis of Alzheimer’s disease. Quantitative analysis is usually performed with standardized uptake value ratios (SUVR), which are calculated by normalizing to a reference region. However, the reference region could present high variability in longitudinal studies. Texture features based on the grey-level co-occurrence matrix, also called Haralick features (HF), are evaluated in this study to discriminate between amyloid-positive and neg

APA, Harvard, Vancouver, ISO, and other styles

31

Lilja, Johan, Antoine Leuzy, Konstantinos Chiotis, Irina Savitcheva, Jens Sörensen, and Agneta Nordberg. "Spatial Normalization of 18F-Flutemetamol PET Images Using an Adaptive Principal-Component Template." Journal of Nuclear Medicine 60, no. 2 (2018): 285–91. http://dx.doi.org/10.2967/jnumed.118.207811.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kim, Jeong-Hoon, Eun-Jeong Lee, Sang-Soon Park, and Jae-Hyeok Heo. "A Case of Early Onset Alzheimer's Disease Diagnosed by 18F Flutemetamol PET Image." Dementia and Neurocognitive Disorders 17, no. 4 (2018): 174. http://dx.doi.org/10.12779/dnd.2018.17.4.174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Wolk, David, Igor Grachev, Christopher Buckley, Kersten Heurling, Roy Hamilton, and Steven Arnold. "P4-078: [18F]-Flutemetamol amyloid PET imaging in patients with normal pressure hydrocephalus." Alzheimer's & Dementia 7 (July 2011): S728. http://dx.doi.org/10.1016/j.jalz.2011.05.2099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Cavallieri, Francesco, Alessandro Fraternali, Annachiara Arnone та ін. "Cerebral Amyloid-β Deposition, Axial Features, and Cognitive Alterations in Patients with Parkinson’s Disease Treated with Bilateral STN-DBS: A Long-Term Cohort Study". Journal of Personalized Medicine 14, № 12 (2024): 1150. https://doi.org/10.3390/jpm14121150.

Full text

Abstract:

Objectives: Our aim was to evaluate the possible long-term cerebral deposition of amyloid-β in patients with PD treated with subthalamic nucleus deep brain stimulation (STN-DBS) and its possible influence on axial and cognitive variables. Methods: Consecutive PD patients treated with bilateral STN-DBS with a long-term follow-up were included. The amyloid-β deposition was evaluated postoperatively through an 18F-flutemetamol positron emission tomography (PET) study. Axial symptoms were assessed using a standardized clinical–instrumental approach. The speech was assessed by perceptual and acoust

APA, Harvard, Vancouver, ISO, and other styles

35

Lundqvist, R., J. Lilja, B. A. Thomas, et al. "Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data." Journal of Nuclear Medicine 54, no. 8 (2013): 1472–78. http://dx.doi.org/10.2967/jnumed.112.115006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

de Lartigue, J. "Flutemetamol (18F): A beta-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis." Drugs of Today 50, no. 3 (2014): 219. http://dx.doi.org/10.1358/dot.2014.050.03.2116672.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Clerc, Olivier F., Shilpa Vijayakumar, Ardel J. Romero Pabon, et al. "Defining the Optimal Imaging Technique With 18F-Flutemetamol PET To Diagnose Transthyretin Cardiac Amyloidosis." Journal of Nuclear Cardiology 38 (August 2024): 102007. http://dx.doi.org/10.1016/j.nuclcard.2024.102007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Senda, Michio, Yasuji Yamamoto, Masahiro Sasaki, et al. "An exploratory efficacy study of the amyloid imaging agent [18F]flutemetamol in Japanese Subjects." Annals of Nuclear Medicine 29, no. 5 (2015): 391–99. http://dx.doi.org/10.1007/s12149-015-0957-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Möckelind, Sofia, Jan Axelsson, Björn Pilebro, Per Lindqvist, Ole B. Suhr, and Torbjörn Sundström. "Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis." Amyloid 27, no. 3 (2020): 191–99. http://dx.doi.org/10.1080/13506129.2020.1760237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

An, Young-Sil, Jung Han Yoon, Sang Joon Son, Chang Hyung Hong, Su Jin Lee, and Joon-Kee Yoon. "Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated." Scientific Reports 11, no. 1 (2021). http://dx.doi.org/10.1038/s41598-021-91891-z.

Full text

Abstract:

AbstractLittle is known about whether early-phase PET images of 18F-FP-CIT match those of amyloid PET. Here, we compared early-phase 18F-FP-CIT and 18F-flutemetamol PET images in patients who underwent both within a 1-month interval. The SUVR on early-phase 18F-FP-CIT PET (median, 0.86) was significantly lower than that of 18F-flutemetamol PET (median, 0.91, p < 0.001) for total brain regions including all cerebral lobes and central structures. This significant difference persisted for each brain region except central structures (p = 0.232). The SUVR of total brain regions obtained from ear

APA, Harvard, Vancouver, ISO, and other styles

41

Rauhala, Elina, Jarkko Johansson, Mira Karrasch, et al. "Change in brain amyloid load and cognition in patients with amnestic mild cognitive impairment: a 3-year follow-up study." EJNMMI Research 12, no. 1 (2022). http://dx.doi.org/10.1186/s13550-022-00928-5.

Full text

Abstract:

Abstract Background Our aim was to investigate the discriminative value of 18F-Flutemetamol PET in longitudinal assessment of amyloid beta accumulation in amnestic mild cognitive impairment (aMCI) patients, in relation to longitudinal cognitive changes. Methods We investigated the change in 18F-Flutemetamol uptake and cognitive impairment in aMCI patients over time up to 3 years which enabled us to investigate possible association between changes in brain amyloid load and cognition over time. Thirty-four patients with aMCI (mean age 73.4 years, SD 6.6) were examined with 18F-Flutemetamol PET s

APA, Harvard, Vancouver, ISO, and other styles

42

Abrahamson, Eric E., Christopher Buckley, Hugh Pemberton, Gill Farrar, Adrian Smith та Milos D. Ikonomovic. "Correlations between [¹⁸F]flutemetamol PET and region‐matched postmortem integrated density measures of cyano‐flutemetamol signal in Aβ plaques". Alzheimer's & Dementia 19, S16 (2023). http://dx.doi.org/10.1002/alz.080306.

Full text

Abstract:

AbstractBackgroundThe binding substrates of [18F]flutemetamol and [11C]PiB PET consist of fibrillar amyloid‐β (Aβ) aggregates in morphologically and structurally distinct diffuse plaques (DP) and cored plaques (CP) which are present at different proportions across brain regions in Alzheimer’s disease (AD). To account for this heterogeneity, an unbiased quantitative measure integrating plaque size and density of amyloid‐β (Aβ) fibrils in plaques could help avoid false positive results, improve imaging‐to‐autopsy correlations, and further advance our understanding of pathological substrates for

APA, Harvard, Vancouver, ISO, and other styles

43

Abrahamson, Eric E., Christopher Buckley, Hugh Pemberton, Gill Farrar, Adrian Smith та Milos D. Ikonomovic. "Correlations between [18F]flutemetamol PET and region‐matched postmortem integrated density measures of cyano‐flutemetamol signal in Aβ plaques". Alzheimer's & Dementia 19, S10 (2023). http://dx.doi.org/10.1002/alz.081997.

Full text

Abstract:

AbstractBackgroundThe binding substrates of [18F]flutemetamol and [11C]PiB PET consist of fibrillar amyloid‐ß (Aß) aggregates in morphologically and structurally distinct diffuse plaques (DP) and cored plaques (CP) which are present at different proportions across brain regions in Alzheimer’s disease (AD). To account for this heterogeneity, an unbiased quantitative measure integrating plaque size and density of amyloid‐ß (Aß) fibrils in plaques could help avoid false positive results, improve imaging‐to‐autopsy correlations, and further advance our understanding of pathological substrates for

APA, Harvard, Vancouver, ISO, and other styles

44

Snellman, Anniina, Johanna Rokka, Francisco R. Lopez-Picon, et al. "In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol." EJNMMI Research 4, no. 37 (2014). https://doi.org/10.1186/s13550-014-0037-3.

Full text

Abstract:

Background: The purpose of the study was to evaluate the applicability of 18F-labelled amyloid imaging positron emission tomography (PET) agent [18F]flutemetamol to detect changes in brain beta-amyloid (Aβ) deposition in vivo in APP23, Tg2576 and APPswe-PS1dE9 mouse models of Alzheimer's disease. We expected that the high specific activity of [18F]flutemetamol would make it an attractive small animal Aβ imaging agent. Methods: [18F]flutemetamol uptake in the mouse brain was evaluated in vivo at 9 to 22 months of age with an Inveon Multimodality PET/CT camera (

APA, Harvard, Vancouver, ISO, and other styles

45

Zeydan, Burcu, Derek R. Johnson, Christopher G. Schwarz, et al. "Visual assessments of 11C-Pittsburgh compound-B PET vs. 18F-flutemetamol PET across the age spectrum." Nuclear Medicine Communications, September 13, 2024. http://dx.doi.org/10.1097/mnm.0000000000001902.

Full text

Abstract:

Objective Visual assessments of amyloid-β PET, used for Alzheimer’s disease (AD) diagnosis and treatment evaluation, require a careful approach when different PET ligands are utilized. Because the gray matter (GM) and white matter (WM) ligand bindings vary with age, the objective was to investigate the agreement between visual reads of 11C- and 18F-PET scans. Methods Cognitively unimpaired (CU) younger adults (N = 30; 39.5 ± 6.0 years), CU older adults (N = 30; 68.6 ± 5.9 years), and adults with AD (N = 22; 67.0 ± 8.5 years) underwent brain MRI, 11C-Pittsburgh compound-B (PiB)-PET, and 18F-flu

APA, Harvard, Vancouver, ISO, and other styles

46

Heeman, Fiona, Maqsood Yaqub, Isadora Lopes Alves, et al. "Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies." Journal of Cerebral Blood Flow & Metabolism, April 11, 2020, 0271678X2091802. http://dx.doi.org/10.1177/0271678x20918029.

Full text

Abstract:

Global and regional changes in cerebral blood flow (CBF) can result in biased quantitative estimates of amyloid load by PET imaging. Therefore, the current simulation study assessed effects of these changes on amyloid quantification using a reference tissue approach for [18F]flutemetamol and [18F]florbetaben. Previously validated pharmacokinetic rate constants were used to simulate time-activity curves (TACs) corresponding to full dynamic and dual-time-window acquisition protocols. CBF changes were simulated by varying the tracer delivery ( K1) from +25 to −25%. The standardized uptake value r

APA, Harvard, Vancouver, ISO, and other styles

47

Bao, Yi-Wen, Anson C. M. Chau, Patrick Ka-Chun Chiu, et al. "Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer’s Disease and Other Dementias." Journal of Alzheimer's Disease, December 23, 2020, 1–14. http://dx.doi.org/10.3233/jad-200890.

Full text

Abstract:

Background: With the more widespread use of 18F-radioligand-based amyloid-β (Aβ) PET-CT imaging, we evaluated Aβ binding and the utility of neocortical 18F-Flutemetamol standardized uptake value ratio (SUVR) as a biomarker. Objective: 18F-Flutemetamol SUVR was used to differentiate 1) mild cognitive impairment (MCI) from Alzheimer’s disease (AD), and 2) MCI from other non-AD dementias (OD). Methods: 109 patients consecutively recruited from a University memory clinic underwent clinical evaluation, neuropsychological test, MRI and 18F-Flutemetamol PET-CT. The diagnosis was made by consensus of

APA, Harvard, Vancouver, ISO, and other styles

48

Sanaat, Amirhossein, Hossein Shooli, Andrew Stephen Böhringer, et al. "A cycle-consistent adversarial network for brain PET partial volume correction without prior anatomical information." European Journal of Nuclear Medicine and Molecular Imaging, February 20, 2023. http://dx.doi.org/10.1007/s00259-023-06152-0.

Full text

Abstract:

Abstract Purpose Partial volume effect (PVE) is a consequence of the limited spatial resolution of PET scanners. PVE can cause the intensity values of a particular voxel to be underestimated or overestimated due to the effect of surrounding tracer uptake. We propose a novel partial volume correction (PVC) technique to overcome the adverse effects of PVE on PET images. Methods Two hundred and twelve clinical brain PET scans, including 50 18F-Fluorodeoxyglucose (18F-FDG), 50 18F-Flortaucipir, 36 18F-Flutemetamol, and 76 18F-FluoroDOPA, and their corresponding T1-weighted MR images were enrolled

APA, Harvard, Vancouver, ISO, and other styles

49

Young, Peter, Fiona Heeman, Jan Axelsson, et al. "Impact of simulated reduced injected dose on the assessment of amyloid PET scans." European Journal of Nuclear Medicine and Molecular Imaging, October 28, 2023. http://dx.doi.org/10.1007/s00259-023-06481-0.

Full text

Abstract:

Abstract Purpose To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [18F]flutemetamol and [18F]florbetaben. Methods Cognitively impaired and unimpaired individuals (N = 250, 36% Aβ-positive) were included and injected with [18F]flutemetamol (N = 175) or [18F]florbetaben (N = 75). PET scans were acquired in list-mode (90–110 min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction

APA, Harvard, Vancouver, ISO, and other styles

50

Bao, Yi-Wen, Yat-Fung Shea, Patrick Ka-Chun Chiu, Joseph S. K. Kwan, Felix Hon-Wai Chan, and Henry Ka-Fung Mak. "Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer’s Disease-related neurodegenerative diseases from an unselected memory clinic cohort." Scientific Reports 12, no. 1 (2022). http://dx.doi.org/10.1038/s41598-022-14532-z.

Full text

Abstract:

AbstractTo evaluate the incremental diagnostic value of 18F-Flutemetamol PET following MRI measurements on an unselected prospective cohort collected from a memory clinic. A total of 84 participants was included in this study. A stepwise study design was performed including initial analysis (based on clinical assessments), interim analysis (revision of initial analysis post-MRI) and final analysis (revision of interim analysis post-18F-Flutemetamol PET). At each time of evaluation, every participant was categorized into SCD, MCI or dementia syndromal group and further into AD-related, non-AD r

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!